Sarepta Therapeutics

clinical hold

gene therapy

3 Best Gene Therapy Stocks of 2018 (So Far)

Motley Fool

Thu, 07/5/18 - 11:04 am

[video/transcript]Sarepta Therapeutics Could Be Onto Something Big

Motley Fool

Mon, 06/25/18 - 07:26 pm

Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday

Motley Fool

Tue, 06/19/18 - 10:42 pm

PTC Therapeutics

risdiplam

Biogen

Ionis Pharmaceuticals

spinal muscular atrophy

Translarna

Emflaza

3 patients add $2.5B to Sarepta's value

Biopharma Dive

Tue, 06/19/18 - 09:45 pm

With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’

Stat

Tue, 06/19/18 - 10:55 am

clinical trials

As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy

Xconomy

Mon, 06/18/18 - 11:25 am

Solid Biosciences

Sarepta CEO Doug Ingram scored a chart-topping $57M compensation deal in 2017. Earning it won’t be easy

SGT-001

Endpoints

Fri, 05/4/18 - 06:45 pm

Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug

Doug Ingram

executive pay

Endpoints

Thu, 05/3/18 - 11:14 pm

Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal

Endpoints

Fri, 04/6/18 - 07:39 pm

Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end

Stat

Mon, 03/12/18 - 09:37 am

Sarepta halts its golodirsen Duchenne MD study in UK after patient experiences adverse event

golodirsen

Exondys 51

Endpoints

Fri, 02/9/18 - 09:35 am

golodirsen

What break? Sarepta vet Ed Kaye quickly pivots to the helm of another biotech upstart with a $40M bankroll

Sarepta is making a bold bet on genetic medicine

Marketwatch

Mon, 01/15/18 - 09:44 am

Endpoints

Thu, 01/4/18 - 11:09 am

Ed Kaye

Stoke Therapeutics

Anthem reverses course, agrees to cover Sarepta's Duchenne drug

BioPharma Dive

Mon, 11/13/17 - 08:46 pm

Anthem

Sarepta readies FDA pitch after a small study spotlights 1% dystrophin add for golodirsen in Duchenne MD

Exondys 51

Endpoints

Wed, 09/6/17 - 09:52 am

New docs spotlight the FDA’s failed attempt to get Sarepta’s flawed Duchenne study retracted

golodirsen

Endpoints

Tue, 08/22/17 - 06:40 pm

eteplirsen

These 3 Biotechs Just Crushed Analyst Expectations

Motley Fool

Mon, 08/7/17 - 01:36 pm

BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta

Endpoints

Tue, 07/18/17 - 09:28 am

Biomarin